61046-58-0

Upstream product

• 7650-91-1 benzyldiphenylphosphane 

Downstream Products

• 72893-65-3 trans-(BzlPPh₂)2Pd(NCS)2 

Relevant academic research and scientific papers

Synthesis, structural characterization and biological screening of heteroleptic palladium(II) complexes

Heteroleptic palladium(II) complexes of the type formula [(DTC)(Pd)(PR3)Cl], where DTC = bis(2-ethylhexyl)dithiocarbamate (1, 8, 9, 10), bis(2-methoxyethyl)dithiocarbamate (2), di-n-decyldithiocarbamate (3, 6), di-n-hexyldithiocarbamate (4, 7), bis(2-methylbutyl)dithiocarbamte (5); PR3 = diphenyl-t-butylphosphine (1), diphenyl-n-propylphosphine (2), triphenylphosphine (3, 4, 5, 10), diphenyl-p-tolylphosphine (6, 7, 8), diphenylbenzylphosphine (9); have been synthesized and characterized by FTIR, Raman, multinuclear and multinuclear NMR (1H, 13C, 31P) spectroscopy and elemental analyses. The structures of complexes (1 and 2) were determined by single-crystal X-ray diffraction. The geometries around the metal centers are pseudo square-planar. The new complexes exhibit moderate anticancer and antibacterial activity.

Anticancer metallopharmaceutical agents based on mixed-ligand palladium(II) complexes with dithiocarbamates and tertiary organophosphine ligands

Mixed-ligand palladium(II) complexes of the type [(DT)Pd(PR 3)Cl], where DT = diethyldithiocarbamate (1), dibutyldithiocarbamate (2,3), dipropyldithiocarbamate (4,5), bis(2-methoxyethyl)dithiocarbamate; PR3 = benzyldiphenylphosphine (1,4), diphenyl-o-tolylphosphine (2), diphenyl-t-butylphosphine (3), P-chlorodiphenylphosphine (5) and triphenylphosphine (6), have been synthesized and characterized by elemental analyses and FT-IR, Raman and multinuclear NMR spectroscopy. The structures of compounds 1 and 2 were determined by single-crystal X-ray diffraction (XRD) measurements and these analyses showed that the complexes have pseudo square-planar geometry around the Pd(II) and that the dithiocarbamate ligand is bound in a bidentate fashion, while the remaining two positions are occupied by a tertiary organophosphine and a chloride ligand. The anticancer studies showed that the Pd(II) complexes are highly active against cisplatin-resistant DU145 human prostate carcinoma (HTB-81) cells with the highest activity shown by compound 6 (IC50 = 2.12 μm). The redox behavior and ds-DNA-denaturing ability of the complexes were studied by cyclic voltammetry and two reduction and one oxidation waves were observed. The decrease in the reduction peak currents illustrated the consumption of the mixed-ligand drug by the DNA molecule. Copyright

Reactions of benzyldiphenylphosphine with Pd(II) sources on silica gel

Depending on the conditions used, reactions of benzyldiphenylphosphine (HL1) with Na2PdCl4 on silica gel or with Pd(OAc)2 on the same absorbent followed by treatment with LiCl provide one or more of the four compounds: the cyclopalladated binuclear complex [(μ-Cl)PdL1]2 (1), cis and trans isomers of the coordination complex PdCl2(HL1)2 (3), the binuclear coordination complex [(μ-Cl)PdCl(HL1)]2 (4), and compound PdCl2(HL1)3 (5). The 56% yield of complex 1 achieved using the reaction with Na2PdCl4 and NaOAc on SiO2 is higher than that reported for the direct cyclopalladation of PBnPh2 with Pd(OAc)2 in AcOH. X-ray diffraction studies of the cyclopalladated dimer 1 and the coordination complex cis-3 are reported.

CYCLOMETALLIERTE Pd- UND Pt-KOMPLEXE DER (o-LITHIOBENZYL)DIORGANOPHOSPHINE

The (o-lithiobenzyl)diorganophosphines o-LiC6H4CH2PR2 (R = Ph, Me, t-Bu) form the corresponding cyclometalated complexes when allowed to react with MCl2*2 Et2S (M = Pd, Pt).Under our reaction conditions they appear to be formed in the cis-form only.Mixed cyclometalated species are described as well as the behaviour of some cyclometalated compounds towards HCl, Br2 and HgBr2 and reactions with n-BuLi.The IR and NMR spectra of the prepared complexes are discussed.